Innoviva, Inc. (INVA)

Pharmaceutical Preparations

Latest Price

$20.84

TTM P/E

4.79

Normalized P/E

9.98

Div Yield

Book Value

16.71

P/B Ratio

1.25

Valuation metrics

EPS: $3.30

Book value / share: $15.71

Formula: √(22.5 × EPS × BVPS)

Graham Number

$34.16

+64% upside

Norm. op. income: $284M (median of 4yr)

Tax rate: 17%

Discount rate: 10%

Growth assumption: zero (EPV is a no-growth value)

Earnings Power Value

$35.42

+70% upside

Base FCF: $196M (median of recent 5yr)

Growth: 10%/yr (median YOY, capped at 25%)

Discount rate: 10%

Terminal growth: 3%

Projection horizon: 10 years

DCF Fair Value

$69.04

+231% upside

EPS: $3.30

Target P/E: 10×

Formula: EPS × P/E

P/E Fair Value

$33.00

+58% upside

100.0% held by institutions

Institution	Shares	Value	Ownership %	Change	Filing Date
BlackRock, Inc.	11.56M	$262.0M	15.91%	+247.4K	2026-06-30
DIMENSIONAL FUND ADVISORS LP	4.49M	$102.0M	6.19%	+57.6K	2026-06-30
VANGUARD PORTFOLIO MANAGEMENT LLC	4.22M	$95.0M	5.81%	-4.7K	2026-06-30
RENAISSANCE TECHNOLOGIES LLC	4.04M	$91.0M	5.56%	-19.1K	2026-06-30
STATE STREET CORP	3.27M	$74.0M	4.50%	+207.6K	2026-06-30
VANGUARD CAPITAL MANAGEMENT LLC	3.16M	$71.0M	4.35%	+16.5K	2026-06-30
MILLENNIUM MANAGEMENT LLC	2.54M	$57.0M	3.50%	+261.7K	2026-06-30
GEODE CAPITAL MANAGEMENT, LLC	2.07M	$47.0M	2.86%	+145.0K	2026-06-30
SYSTEMATIC FINANCIAL MANAGEMENT LP	2.02M	$45.0M	2.79%	-517	2026-06-30
Boston Partners	1.93M	$43.0M	2.65%	+209.1K	2026-06-30